Ticker League

EBITDA for Regeneron Pharmaceuticals (REGN)

Latest filings through · Reported

Metric

TTM

$5.74B

YoY change

+9.4%

5Y CAGR

+7.2%

Peak year (2021)

$9.67B

EBITDA history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: $5.82B

EBITDA growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: +9.4%

EBITDA history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

  • 2025$5.82B+9.4%
  • 2024$5.32B+13.3%
  • 2023$4.69B-10.8%
  • 2022$5.26B-45.6%
  • 2021$9.67B+135.7%
  • 2020$4.10B+53.7%
  • 2019$2.67B-2.2%
  • 2018$2.73B+21.4%
  • 2017$2.25B+56.0%
  • 2016$1.44B+9.7%
  • 2015$1.31B+51.8%
  • 2014$865.80M+8.1%
  • 2013$801.00M+61.3%
  • 2012$496.67M-391.3%
  • 2011−$170.53M+125.4%
  • 2010−$75.66M+36.7%
  • 2009−$55.37M-9.7%
  • 2008−$61.32M-25.3%
  • 2007−$82.07M+7.3%
  • 2006−$76.52M+12.7%
  • 2005−$67.90M-198.1%
  • 2004$69.24M-175.7%
  • 2003−$91.51M-19.4%
  • 2002−$113.50M+42.6%
  • 2001−$79.61M+281.7%
  • 2000−$20.86M+2.2%
  • 1999−$20.40M+114.7%
  • 1998−$9.50M+2.2%
  • 1997−$9.30M-17.0%
  • 1996−$11.20M+558.8%
  • 1995−$1.70M-93.2%
  • 1994−$25.00M-30.0%
  • 1993−$35.70M+119.0%
  • 1992−$16.30M+85.2%
  • 1991−$8.80M+193.3%
  • 1990−$3.00M—

EBITDA values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Regeneron Pharmaceuticals (REGN)

According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $5.74B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of Regeneron Pharmaceuticals (REGN) EBITDA is $5.82B – grew 9.4% year-over-year.

Across 2020–2025 (5 years), Regeneron Pharmaceuticals EBITDA produced a CAGR of +7.2% – sustaining 2 straight years of year-over-year growth.

Regeneron Pharmaceuticals EBITDA plunged from $9.67B in 2021 to $5.82B in 2025, a 39.8% drawdown.

$9.67B stands as the all-time-high annual EBITDA, posted in 2021, against a low of −$170.53M during 2011.

Regeneron Pharmaceuticals EBITDA by Year

Regeneron Pharmaceuticals EBITDA 2025: $5.82B

2025's EBITDA for Regeneron Pharmaceuticals came in at $5.82B, grew 9.4% from 2024.

Regeneron Pharmaceuticals EBITDA 2024: $5.32B

Regeneron Pharmaceuticals posted EBITDA of $5.32B in 2024, grew 13.3% from 2023.

Regeneron Pharmaceuticals EBITDA 2023: $4.69B

In 2023, Regeneron Pharmaceuticals reported EBITDA of $4.69B, declined 10.8% below 2022.

Regeneron Pharmaceuticals EBITDA 2022: $5.26B

Regeneron Pharmaceuticals EBITDA in 2022 was $5.26B, plunged 45.6% below 2021.

Regeneron Pharmaceuticals EBITDA 2021: $9.67B

Regeneron Pharmaceuticals EBITDA in 2021 was $9.67B.

See more financial history for Regeneron Pharmaceuticals (REGN).

Sector peers by EBITDA

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest EBITDA

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation